Patent intelligence · US
US 12065404
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
Patent details — US 12065404
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 20, 2024
- Expiration
- Aug 15, 2044
- Applicant
- Enveric Biosciences Canada Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
Quick answer
US 12065404 (C4-carboxylic acid-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enveric Biosciences Canada Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
More from Enveric Biosciences Canada Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428408
Fused heterocyclic mescaline derivatives
granted -
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133856
Multi-substituent psilocybin derivatives and methods of using
granted
Frequently asked questions
What is US patent 12065404?
US 12065404 (C4-carboxylic acid-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12065404?
Enveric Biosciences Canada Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 12065404 expire?
Our index shows an expiration date of Aug 15, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.